

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :	A1	(11) International Publication Number: WO 93/20784
A61F 9/00, A61M 5/32		(43) International Publication Date: 28 October 1993 (28.10.93)

(21) International Application Number: PCT/US93/03379	(74) Agent: NOONAN, Kevin, E.; Allegretti & Witcoff, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US).
(22) International Filing Date: 9 April 1993 (09.04.93)	
(30) Priority data: 866,561 10 April 1992 (10.04.92) US	(81) Designated States: AU, CA, FI, JP, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant: STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDU- CATION on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97201-3098 (US).	Published <i>With international search report.</i>
(72) Inventors: MORRISON, John, C. ; 2620 S.W. Gardenview Avenue, Portland, OR 97225 (US). MOORE, Chester, G. ; 4816 S.E. Salmon Street, Portland, OR 97215 (US).	

(54) Title: A MICRONEEDLE FOR INJECTION OF OCULAR BLOOD VESSELS



(57) Abstract

This invention is a device for microvascular injection and a method for treating glaucoma using the device. The device comprises a reservoir (11) attached to a blunted needle (12) connected to a flexible tapered tubing (13), at the end of which is positioned a microneedle (14) or micropipette for inserting into small blood vessels. The invention also provides a method for treating glaucoma and other diseases wherein microinjection of disease-ameliorating drugs into small blood vessels and their capillary beds would be therapeutically effective.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam

## A MICRONEEDLE FOR INJECTION OF OCULAR BLOOD VESSELS

### BACKGROUND OF THE INVENTION

5        This invention was made with government support under Grant #1-2-409-540 by the Veterans' Administration. The government has certain rights in the invention.

10      **1. Field of The Invention**

The present invention relates to a device which enables microvascular injections and manipulations directly into delicate and otherwise inaccessible blood vessels such as the capillary beds of the eye, thus providing means for more effectively treating diseases of the eye such as glaucoma.

15      **2. Background of the Invention**

20       Glaucoma is an ophthalmic disease which is manifested in most patients by an increase in intraocular pressure (normally equal to 5-25 mm of Hg) sufficient to cause degeneration of the optic nerve and defects in the visual field. It is a major cause of preventable blindness, affecting 2% of the adult population. Clinically, it is characterized by a specific type of optic nerve damage which accompanies the pathological increase in intraocular pressure. Most instances of elevated intraocular pressure are due to increased resistance to aqueous humor outflow from the trabecular meshwork, a sieve-like ringed structure located at the juncture of the iris and cornea.

25       Conventional glaucoma therapy concentrates on lowering intraocular pressure, either through eye drops, laser treatments, or surgery, all of which have significant drawbacks. Eye drops have been prescribed (either alone or usually in combination) either to inhibit the secretion of aqueous humor by the ciliary processes ("beta-blockers") or to improve escape of aqueous humor from the eye (such as pilocarpine, the miotic). To be effective, however, these drugs need to be administered in highly concentrated dosages because of poor penetration of the drugs into the eye. The administration of these drugs in such highly concentrated

dosages creates a strong potential for ocular and systemic side effects, since much of these drugs drain into the nose and are absorbed into the bloodstream through the nasal lining. This is particularly a problem when the drugs must be administered on a continuous basis over a patient's lifetime.

5       Laser treatment is often used as an alternative or in addition to drug treatment, but the results are variable and often transient. The best current surgical treatment involves creating a channel for the fluid to escape out of the eye, thereby lowering the intraocular pressure. Although effective in controlling the eye pressure, this surgery has significant potential for producing sight-threatening complications including infection and bleeding, especially immediately 10      after surgery (when eye pressure suddenly and dramatically decreases).

15      Accordingly, there is a need for new therapeutic approaches to lower intraocular pressure, using agents to alter the function of the trabecular meshwork permanently or at least on a prolonged basis. An important step towards such a therapy would be direct delivery of the agent into the trabecular meshwork. This approach would eliminate the problems of ocular or systemic side effects which have been encountered heretofore with the chronic therapeutic use of eye drops given in highly concentrated dosages. In addition, the margin of safety of such a therapy would be greatly improved over surgery if the administered drug acted 20      gradually to lower intraocular pressure.

Micropipettes have been used in diagnostic procedures.

U.S. Patent 3,986,834 discloses a kit in which a micropipette may be included for transferring reagents undergoing analysis of blood urea.

25      U.S. Patent 4,050,316 discloses the use of an aspirator with a micropipette.

U.S. Patent 4,078,892 discloses the use of a micropipette in transforming plasma into a diazo reagent for the determination of bilirubin.

Toth *et al.*, 1992, Amer. J. Ophthalmol. 113: 175-182 disclose ultramicrosurgical removal of subretinal hemorrhage in cats using a microneedle.

30      Frenkel *et al.*, 1989, Vestn. Oftalmol. 105: 27-29 disclose the optimal shape of microneedles for suturing solid biological tissues, and the use of such

needles for ophthalmological surgery.

Hori *et al.*, 1983, *Gann* 74: 122-127 disclose the use of micropipetted to partially occlude microvessels without disturbing microcirculation.

5

## SUMMARY OF THE INVENTION

The present invention relates to a device comprising in combination a reservoir, preferably a syringe, most preferably a syringe having a volume of 1-2 cubic centimeters, the syringe having attached thereto a blunt needle, preferably a blunted hypodermic needle. Attached to the needle is a piece of flexible tapered tubing suitable for dispensing ophthalmic solutions; suitable tubing is preferably polyethylene tubing, most preferably PE-50 tubing, tapered to a degree that the wider end of the tubing fits over the blunt needle and the narrower end fits over a microneedle. The microneedle comprises a glass micropipette or a metallic microneedle wherein one end of the microneedle is attached to the narrower end of the tubing. The other end of the microneedle is preferably beveled. The device of the invention is useful for insertion into small blood vessels *in vivo*, in particular the aqueous vessels leading from the trabecular meshwork of the eye.

The present invention also includes within its scope a method for the treatment of glaucoma using the device provided by the invention.

20

## BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1 through 4 are schematics of the device of the present invention. Figures 5A and 5B are scanning electron micrographs of a glass microneedle tip which has been beveled and magnified 1000 times. Figure 6 is an illustration of the relationship of the trabecular meshwork 15 to Schlemm's canal 16 in the normal human eye. Figure 7 is a schematic of a diagram of Schlemm's canal and its associated collector channels and their relationship to sclera 17 and aqueous veins 18 located on the surface of the eye.

30

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A complete understanding of the invention may be better obtained by

referring to the accompanying drawings, Figures 1 to 4 inclusive. In Figure 1, there is seen a reservoir, preferably having a small-volume plunger-type syringe 11 (most preferably having a volume of 1 to 2 cubic centimeters), having attached at the discharge end a needle 12, preferably a blunted hypodermic needle (Figure 5). The needle may be made of stainless steel, hyperchrome steel, carbon steel, chromium, nickeloid, platinum, platinumuridium, silver or gold. Attached to the blunted end of the needle is a piece of ophthalmologically acceptable tapered tubing 13 about 6 - 12 inches in length and constructed of any flexible polymeric materials, including but not limited to polyethylene, polypropylene, and like polymeric materials which are inert chemically. The tubing is tapered to a degree that the wider end of the tubing fits over the blunted hypodermic needle and the narrower end fits over a microneedle (Figure 2). At the narrower end of the tubing 13, there is positioned a microneedle 14. This aspect of the invention may be seen more clearly in Figure 3A and 3B. In one embodiment of the invention, 10 the microneedle comprises a drawn or pulled out glass micropipette. In other embodiments, the microneedle is made of any fine material, including but not limited to stainless steel, hyperchrome steel, carbon steel, chromium, nickeloid, platinum, platinumuridium, silver or gold. Suitable needles may be about 20 to 15 100 microns wide and 1-5 mm long. In a preferred embodiment, the tip of the microneedle is beveled, as shown in Figures 5A and 5B. The flexible tubing is operatively linked at one end to the hypodermic needle and at the other end to the microneedle (Figure 2). For the purposes of this invention, the term "operatively linked" means physically joined so as to permit fluid flow without leaking. The joints between the needle 12 and the tubing 13 and between the tubing and the 20 micropipette or microneedle 14 are secured to prevent leakage, preferably by glue or other suitable material. At the junction of the needle and the tubing, a small amount of glue or other rigid material forms a rigid spherical gripping means 22 that surrounds the tapered tubing at the junction of the tubing with the microneedle (Figures 2 and 3). The gripping means 22 provides a contact point for holding the microneedle with forceps or other suitable instruments. This 25 feature of the invention allows virtually any orientation to be achieved and 30

maintained by the operator during microvascular injection using the device. In a preferred embodiment, the gripping means comprises a ball of glue.

Figure 6 illustrates the trabecular meshwork 15 to Schlemm's canal 16 in a normal human eye. Normally, aqueous humor flows through the trabecular meshwork 15 and into Schlemm's canal 16. Schlemm's canal 16 is drained through the sclera 17 into episcleral aqueous veins 18. Figure 7 illustrates Schlemm's canal 16 and its associated collector channel 20 and their relationship to the aqueous veins 18. Clinically, most of these veins 18 are filled with blood but many are clearly identifiable by a clear column of aqueous humor running beside the red blood cells.

In the practice of the present invention in treating glaucoma, the syringe is filled with an ophthalmic solution containing a therapeutic agent, preferably one which lowers intraocular pressure by reducing resistance to outflow through the trabecular network. The microneedle 14 is inserted into one of the aqueous veins 18, and the plunger of the syringe 11 is depressed allowing the solution to be delivered directly to the trabecular meshwork 15. Using the microneedle 14 according to the present invention allows the direct entry of therapeutic agents into the delicate and otherwise inaccessible trabecular meshwork of the eye. Although the inner diameter of the needle 14 is small, it is sufficiently large to permit the injection of significant amounts of ophthalmic solutions at effective rates (at least 0.1 cc per 15-60 seconds). This is a significant development as the entire volume of the front chamber of the eye is about 0.25 cc.

Depending on the clinical condition of the patient, the microneedle 14 could be inserted with local or in some cases even topical anesthetics, including but not limited to xylocaine and proparacaine-HCl.

In addition to agents designed to reduce trabecular meshwork resistance, other therapeutic agents, [such as antibiotics or antibacterials (such as tetracyclines), steroids (such as hydrocortisone), and the like] may also be delivered to the eye with this device to treat pathological conditions other than glaucoma, such as intraocular infection or inflammation.

While the device of the present invention has been described with

particular reference to the eye, it will be obvious to those skilled in the art that this invention has applications in other medical fields whenever direct microsurgical injection is indicated to deliver therapeutic agents to discrete microvascular beds. An example would be neurosurgical oncology when direct injection of potent anticancer agents could be performed to treat otherwise inaccessible tumors. By allowing access to very small blood vessels with their small perfusion beds, the device according to the present invention would allow discrete injection of highly potent therapeutic agents with minimal side effects or damage to normal tissues.

In a commercial embodiment of the present invention, the device is sterilized, preferably by gas sterilization such as by exposure to ethylene oxide gas. The syringe is then filled with a sterile ophthalmic solution using aseptic procedures. The device is then packaged with plastic, such as a low density polyethylene, and sterilized again, preferably with ethylene oxide. Alternatively, the device can be packaged and sterilized prior to filling and the syringe filled with sterile therapeutic agent immediately prior to use.

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

**WHAT WE CLAIM IS:**

1. A device for microvascular injection of a solution into a small blood vessel *in vivo*, comprising in combination:

5

a) a reservoir comprising a syringe and a hypodermic needle;

10

b) a flexible tubing having a tapered bore and a first end and a second end, the first end of the flexible tubing being operatively linked to the hypodermic needle, wherein the bore of the tapered tubing at the first end is sufficient to fit over the hypodermic needle; and

15

c) a microneedle having a first end and a second end, the first end of the microneedle being operatively linked to the second end of the flexible tubing, wherein the bore of the flexible tubing at the second end is sufficient to fit over the first end of the microneedle, and the second end of the microneedle having an outer diameter of about 20 microns to about 100 microns.

2. A device according to claim 1 wherein the second end of the microneedle is beveled.

20

3. A device according to claim 2 wherein the microneedle is a drawn glass micropipette.

4. A device according to claim 1 wherein the hypodermic needle is blunted.

5. A device according to claim 1 having rigid spherical gripping means surrounding the tapered bore of the second end of the flexible tubing.

25

6. A device according to claim 5 wherein the rigid spherical gripping means comprises a bead of glue.

7. A device according to claim 1 wherein the syringe has a volume of 1 to 2 cubic centimeters.

30

8. A device according to claim 1 wherein the flexible tubing is constructed of polyethylene plastic.

9. A device according to claim 1 in which the syringe contains an

intraocular pressure lowering agent.




10. A device according to claim 1 in which the syringe contains an antibacterial agent.

5 11. A device according to claim 1 in which the syringe contains an anti-inflammatory agent.

12. A device according to claim 1 in which the syringe contains an anti-cancer agent.

10 13. A method for the treatment of glaucoma which comprises inserting a microneedle into aqueous veins of a patient's eye and injecting an amount of an intraocular pressure lowering agent.

14. A method according to claim 13 wherein the intraocular pressure lowering agent is injected at a rate of about 0.1 to about 0.6 cubic centimeters per minute.






FIG. 2





Figure 5A


Figure 5B

Figure 6



4/5

**SUBSTITUTE SHEET**

Figure 7

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/03379

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 13, 14  
because they relate to subject matter not required to be searched by this Authority, namely:  
Please see Rule 39.1(iv) PCT
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/03379

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC  
 Int.Cl. 5 A61F9/00; A61M5/32

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	A61F ; A61M

Documentation Searched other than Minimum Documentation  
 to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>

III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	AMERICAN JOURNAL OF OPHTHALMOLOGY no. 113, 1 February 1992, NEW YORK pages 175 - 182 TOTH ET AL 'Ultramicrosurgical Removal of Subretinal Hemorrhage in Cats' cited in the application see page 176 ---	1-12
A	US,A,4 909 783 (MORRISON) 20 March 1990 see the whole document -----	1-12

"Special categories of cited documents :<sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search Date of Mailing of this International Search Report

02 JULY 1993

03.08.93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

CLARKSON P.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9303379  
SA 73563

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 02/07/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4909783	20-03-90	None	-----

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**